The U.S. continues to charge significantly higher prices for prescription drugs compared to similarly wealthy countries.

Novartis’ challenge to Pfizer’s blockbuster breast cancer drug, Ibrance, is building momentum, after the US regulator granted it a fast review. The US Food and Drug Administration granted the ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Ibrance is under clinical development by Pfizer and currently in Phase II for Metastatic Brain Tumor. According to GlobalData, Phase II drugs for Metastatic Brain Tumor have a 20% phase transition ...

Ibrance was first approved in 2015 as a treatment for breast cancer patients who had progressed after hormone therapy, and buoyed by expanded use as a first-line therapy has grown swiftly to reach ...

Pfizer said Thursday its drug Ibrance showed efficacy in a group of breast cancer patients who do not currently have access to the medicine, potentially expanding its use. Ibrance, which generates ...

The increases are to list prices, which do not include rebates to pharmacy benefit managers and other discounts.

Healthcare giant Pfizer’s IBRANCE (palbociclib) as a combination therapy has improved progression-free survival from a Phase ...

The top 10 patented drugs getting expired in the coming years in the US, include Pembrolizumab, sold under the brand name ...

The price of branded prescription drugs will rise an average of 4.5% in 2025, the same increase as was seen in 2024, ...

(RTTNews) - Pfizer Inc. (PFE), on Thursday, announced positive results from the Phase 3 PATINA trial, evaluating the addition of IBRANCE for treating metastatic breast cancer. The trial ...

NEW YORK CITY, New York: At the start of 2025, drug companies raised prices on over 250 brand-name medications in the U.S., ...